SEATTLE — A post hoc analysis of the GATHER1 and GATHER2 trials showed the positive effect of avacincaptad pegol treatment in reducing progressive photoreceptor ellipsoid zone attenuation over time.
The ellipsoid zone (EZ) and the photoreceptors are a key marker that have been linked to visual function in multiple retinal diseases.
“In dry macular degeneration, ellipsoid zone integrity has been found to be a marker not only of functional loss but also risk of GA progression,” Justis P. Ehlers, MD, said at the American Society of Retina Specialists annual meeting.